PDCD1 and cancer: Immunoglobulin, immunoreceptor tyrosine-based inhibitory motif domains of T cell immunoreceptors, and PD1 double-positive T cells (DPOS) are present in the peripheral blood of patients with cancer and can serve as markers for predicting response to anti-PD-(L)1 therapy.